Suppr超能文献

Fendrix® 对比 Engerix® 在初始和加强免疫接种方案无应答的 HIV 感染患者中的应用。

Fendrix® compared to Engerix® in HIV-infected patients nonresponding to initial- and re-vaccination schedule.

机构信息

Department of Internal Medicine-Infectious Diseases, Erasmus Medical Center, Rotterdam, the Netherlands.

出版信息

Neth J Med. 2020 Dec;78(6):376-380.

Abstract

BACKGROUND

In HIV-infected patients, the immunogenicity of hepatitis B vaccines is impaired. In this randomised controlled study (RCT), we investigated the effect of Fendrix® versus double-dose Engerix® vaccination in previously non-responsive HIV-infected subjects.

METHODS

Patients included those who were HIV-infected and non-responders to a primary (single-dose hepatitis B (HBV) vaccination) and a subsequent double-dose HBV revaccination schedule. Subjects were randomised 1:1 to receive Fendrix® (t = 0, 4, 8, 24 weeks) or double-dose Engerix® (t = 0, 4, 24 weeks) vaccinations. Primary efficacy, defined as anti-HBs response ≥ 10 IU/l, was evaluated at week 28 in both study arms.

RESULTS

A subset of 48 patients non-responsive to HBV vaccination was selected, from a cohort of patients at our institution, who underwent HBV vaccination unsuccessfully either in a previous RCT or through standard care. The anti-HBs ≥ 10 IU/l response rate at week 28 in the Fendrix® arm and the Engerix® arm were 85.7% and 65.0%, respectively (p = 0.09). There was no significant difference between the two used vaccine types in the anti-HBs levels reached. In our institution, the overall response rate after initial standard-dose vaccination schedule and double-dose revaccination in our cohort was 75%. In this study, combining the effects of Fendrix and Engerix resulted in a 75% response rate in the 25% remaining non-responders on initial and double-dose revaccination series. This yielded an absolute 19% increase and an overall response to HBV vaccination in HIV-infected patients of around 94% in our cohort.

CONCLUSION

These results together, suggest that continuing HBV vaccination in non-responders to a first course of single-dose vaccine and a double-dose revaccination scheme is worth the effort. No superiority of one of the investigated hepatitis B vaccines was shown in this cohort but an appropriate number of patients needed to achieve reliable answers was not achieved.

摘要

背景

在 HIV 感染者中,乙型肝炎疫苗的免疫原性受损。在这项随机对照研究(RCT)中,我们研究了 Fendrix®与双剂量 Engerix®疫苗接种在既往无应答的 HIV 感染者中的效果。

方法

纳入的患者为 HIV 感染者,对初次(单剂量乙型肝炎(HBV)疫苗接种)和随后的双剂量 HBV 再接种方案无应答。将受试者按 1:1 随机分配至接受 Fendrix®(t = 0、4、8、24 周)或双剂量 Engerix®(t = 0、4、24 周)疫苗接种。在两个研究组中,均在第 28 周评估主要疗效终点,即抗-HBs 反应≥10 IU/l。

结果

从我们机构的患者队列中选择了一组 48 例对 HBV 疫苗接种无应答的患者,他们在之前的 RCT 或常规护理中接受 HBV 疫苗接种不成功。Fendrix®组和 Engerix®组在第 28 周的抗-HBs≥10 IU/l 应答率分别为 85.7%和 65.0%(p = 0.09)。两种疫苗在达到的抗-HBs 水平方面没有显著差异。在我们的机构中,我们队列中初始标准剂量疫苗接种方案和双剂量再接种后的总体应答率为 75%。在这项研究中,将 Fendrix 和 Engerix 的效果结合起来,在最初和双剂量再接种系列中,对 25%的无应答者,使应答率达到 75%。这使得我们队列中 HIV 感染者对 HBV 疫苗接种的总体应答率增加了 19%左右,达到了 94%左右。

结论

这些结果表明,继续对首次单剂量疫苗接种和双剂量再接种方案无应答的患者进行 HBV 疫苗接种是值得的。在本队列中,没有显示出两种研究疫苗中的任何一种具有优势,但没有达到实现可靠答案所需的适当患者数量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验